Explore
Bacteriophages
0 Ungluers have
Faved this Work
Login to Fave
There is talk of an upcoming antibiotic armageddon, with untreatable post-operative infections, and similarly untreatable complications after chemotherapy. Indeed, the now famous “O’Neill Report” (https://amr-review.org/) suggests that, by 2050, more people might die from antibiotic-resistant bacterial infections than from cancer. While we are still learning all the subtle drivers of antibiotic resistance, it seems increasingly clear that we need to take a “one health” approach, curtailing the use of antibiotics in both human and veterinary medicine. However, there are no new classes of antibiotics on our horizon. Maybe something that has been around “forever” can come to our rescue—bacteriophages! Nevertheless, it is also necessary to do things differently, and use these new antimicrobials appropriately. Therefore, an in-depth study of bacteriophage biology and case-by-case applications might be required. Whilst by no means comprehensive, this book does cover some of the many topics related to bacteriophages as antimicrobials, including their use in human therapy and aquaculture. It also explores the potential use of phage endolysins as substitutes of antibiotics in two sectors where there is an urgent need—human therapy and the agro-food industry. Last but not least, there is an excellent perspective article on phage therapy implementation.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 180 times via unglue.it ebook links.
- 54 - pdf (CC BY) at Unglue.it.
- 126 - pdf (CC BY) at res.mdpi.com.
Keywords
- Aeromonas hydrophila
- Aeromonas salmonicida
- agent based
- American Foulbrood
- antibacterial
- antibiotic
- antibiotic resistance
- Antibiotic-resistant bacteria
- antibiotics
- antimicrobial
- antimicrobial agent
- antimicrobial resistance
- antimicrobials
- Aquaculture
- bacterial phage resistance
- bacteriophage
- bacteriophage therapy
- bacteriophages
- Biofilm
- Biofilms
- Biological control
- Brevibacillus laterosporus
- bystander phage therapy
- CBD-independent
- challenge trials
- Clostridium difficile
- Clostridium difficile infection
- CRISPR CAS
- dairy industry
- diabetic foot ulcer
- directed evolution
- dual-species
- endolysin
- enzybiotics
- Evolution
- fermentation failure
- fish larvae
- FoldX
- furunculosis
- horizontal gene transfer, transduction
- in vitro fermentation model
- Infrared spectroscopy
- interactions
- Kayvirus
- Lactic acid bacteria
- lysin
- lysins
- lysogenic conversion
- lytic enzyme
- marine vibrios
- MAS
- mass action
- medicine
- microbiome
- microbiome therapy
- models
- Motile Aeromonas Septicemia
- MRSA
- multiple-antibiotic-resistance
- mycobacteriophages
- Mycobacterium smegmatis
- Nagoya Protocol
- One Health
- osteomyelitis
- Paenibacillus larvae
- pathogens
- peptidoglycan hydrolase
- phage
- phage display
- phage isolation
- phage resistance
- phage therapy
- phage-resistant mutants
- PlyC CHAP
- prophage induction
- Protein Engineering
- protein net charge
- Proteins
- Pseudomonas aeruginosa
- read recruitment
- regression modeling
- Resistance
- Safety
- sequential
- Shiga toxin
- simultaneous
- Staphylococcus
- Staphylococcus aureus
- STEC O145 strains
- STEC-specific bacteriophage
- striped catfish (Pangasianodon hypophthalmus)
- synergy
- Treatment
- Vibrio anguillarum
- vibriosis
- whole genome sequencing
Links
DOI: 10.3390/books978-3-03943-405-3Editions